130 related articles for article (PubMed ID: 19590992)
1. Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis.
Tazawa K; Katoh N; Shimojima Y; Matsuda M; Ikeda S
Amyloid; 2009; 16(3):183-5. PubMed ID: 19590992
[TBL] [Abstract][Full Text] [Related]
2. Marked shrinkage of amyloid lymphadenopathy after an intensive chemotherapy in a patient with IgM-associated AL amyloidosis.
Tazawa K; Katoh N; Shimojima Y; Matsuda M; Ikeda S
Amyloid; 2009 Dec; 16(4):243-5. PubMed ID: 19922338
[TBL] [Abstract][Full Text] [Related]
3. AL amyloidosis manifesting as systemic lymphadenopathy.
Matsuda M; Gono T; Shimojima Y; Yoshida T; Katoh N; Hoshii Y; Yamada T; Ikeda S
Amyloid; 2008 Jun; 15(2):117-24. PubMed ID: 18484338
[TBL] [Abstract][Full Text] [Related]
4. Surgical removal of amyloid-laden lymph nodes: a possible therapeutic approach in a primary systemic AL amyloidosis patient with focal lymphadenopathy.
Matsuda M; Katoh N; Tazawa K; Shimojima Y; Mishima Y; Sano K; Ikeda S
Amyloid; 2011 Jun; 18(2):79-82. PubMed ID: 21401322
[TBL] [Abstract][Full Text] [Related]
5. Serum levels of free light chain before and after chemotherapy in primary systemic AL amyloidosis.
Matsuda M; Yamada T; Gono T; Shimojima Y; Ishii W; Fushimi T; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):428-33. PubMed ID: 15942088
[TBL] [Abstract][Full Text] [Related]
6. High-dose melphalan followed by autologous stem cell support in primary systemic AL amyloidosis with multiple organ involvement.
Shimojima Y; Matsuda M; Ishii W; Koyama J; Yamamoto K; Shimodaira S; Sakashita K; Koike K; Ikeda S
Intern Med; 2005 May; 44(5):484-9. PubMed ID: 15942100
[TBL] [Abstract][Full Text] [Related]
7. [Current treatment of AL amyloidosis].
Kovacsovics T
Rev Med Suisse Romande; 2000 Oct; 120(10):771-5. PubMed ID: 11109905
[TBL] [Abstract][Full Text] [Related]
8. [Complete remission of nephrotic syndrome and improvement of renal function in a patient with light chain deposition disease following high dose chemotherapy with transplantation of autologous haematopoietic stem cells. A case study and review of literature].
Adam Z; Krejcí M; Pour L; Stepánková S; Cermáková Z; Voska L; Teplan V; Krivanová A; Hájek R; Mayer J
Vnitr Lek; 2009 Nov; 55(11):1089-96. PubMed ID: 20017442
[TBL] [Abstract][Full Text] [Related]
9. [Heart transplantation and the subsequent treatment of AL amyloidosis].
Adam Z; Krejčí J; Krejčí M; Němec P; Spinarová L; Zampachová V; Cermáková Z; Pika T; Pour L; Kořístek Z; Tomíška M; Szturz P; Král Z; Mayer J
Vnitr Lek; 2013 Feb; 59(2):136-47. PubMed ID: 23461404
[TBL] [Abstract][Full Text] [Related]
10. [A case of primary amyloidosis].
Ardashev VN; Potekhin NP; Rukavitsyn OA; Borisov AG; Malysheva SA
Klin Med (Mosk); 2006; 84(6):56-9. PubMed ID: 16875072
[TBL] [Abstract][Full Text] [Related]
11. New therapeutic approaches in primary systemic AL amyloidosis.
Sezer O; Eucker J; Schmid P; Possinger K
Ann Hematol; 2000 Jan; 79(1):1-6. PubMed ID: 10663614
[TBL] [Abstract][Full Text] [Related]
12. Clinical presentation and treatment responses in IgM-related AL amyloidosis.
Sissoko M; Sanchorawala V; Seldin D; Sworder B; Angelino K; Broce M; Berk J; Sloan JM
Amyloid; 2015; 22(4):229-35. PubMed ID: 26488936
[TBL] [Abstract][Full Text] [Related]
13. Primary amyloidosis presenting with massive generalized lymphadenopathy.
Kutlay S; Hasan T; Keven K; Nergizoglu G; Ates K; Karatan O
Leuk Lymphoma; 2002 Jul; 43(7):1501-3. PubMed ID: 12389637
[TBL] [Abstract][Full Text] [Related]
14. No regression of renal AL amyloid in monoclonal gammopathy after successful autologous blood stem cell transplantation and significant clinical improvement.
Zeier M; Perz J; Linke RP; Donini U; Waldherr R; Andrassy K; Ho AD; Goldschmidt H
Nephrol Dial Transplant; 2003 Dec; 18(12):2644-7. PubMed ID: 14605290
[TBL] [Abstract][Full Text] [Related]
15. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
16. [Therapy options in systemic AL-amyloidosis with renal involvement].
Hetzel GR; Schneider P; Mondry A; Heering P; Heyll A; Grabensee B
Dtsch Med Wochenschr; 2000 Aug; 125(34-35):997-1002. PubMed ID: 11004911
[TBL] [Abstract][Full Text] [Related]
17. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
Comenzo RL
Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
[TBL] [Abstract][Full Text] [Related]
18. Oral cyclic melphalan and dexamethasone for patients with AL amyloidosis.
Sanchorawala V; Seldin DC; Berk JL; Sloan JM; Doros G; Skinner M
Clin Lymphoma Myeloma Leuk; 2010 Dec; 10(6):469-72. PubMed ID: 21156464
[TBL] [Abstract][Full Text] [Related]
19. Treatment of IgM-associated AL amyloidosis with the combination of rituximab, bortezomib, and dexamethasone.
Palladini G; Foli A; Russo P; Milani P; Obici L; Lavatelli F; Merlini G
Clin Lymphoma Myeloma Leuk; 2011 Feb; 11(1):143-5. PubMed ID: 21454217
[TBL] [Abstract][Full Text] [Related]
20. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease.
Casserly LF; Fadia A; Sanchorawala V; Seldin DC; Wright DG; Skinner M; Dember LM
Kidney Int; 2003 Mar; 63(3):1051-7. PubMed ID: 12631087
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
